Investors who already hold CB stock should retain it, as this insurance behemoth is unlikely to disappoint. New investors can wait for a better entry point.

Dell Technologies (DELL -11.45%) stock tumbled 11% through 10:05 a.m. ET Wednesday after the company reported mixed earnings last night.

Amgen's MariTide shows up to 20% weight loss in Phase II, leaving room for improvement beyond 52 weeks, as weight loss did not plateau. GI side effects are a concern, but Amgen plans to address them through dose escalation strategies. The convenience of monthly or less frequent dosing leads to a differentiated profile. MariTide's potential as the first monthly treatment for type 2 diabetes enhances its competitive edge.

Despite rising home prices, a housing shortage boosts demand, making homebuilding stocks, especially Beazer Homes USA, a strong long-term investment. Beazer Homes USA saw a 17.6% share increase since June and a 78.3% rise since January 2022, outperforming the S&P 500. Revenue rose 5.6% in 2024, but profits and cash flows declined due to rising costs; however, operating cash flow surged in the final quarter.

China stock and fintech leader Qifu is rallying to new highs this week, taking out a buy point on the stock market today. The post Chinese Fintech Stock Qifu Hits Buy Point As Profit Growth Accelerates appeared first on Investor's Business Daily.

Does Gladstone Commercial (GOOD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does Kemper (KMPR) have what it takes to be a top stock pick for momentum investors? Let's find out.

NRx Pharmaceuticals (NRXP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Does Allstate (ALL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Gap (GAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).